Acumen Pharmaceuticals Inc. Common Stock (ABOS)

About ABOS

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc.…

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Employees

60

Website

acumenpharm.com/

Fundamentals

1-day range

$2.79$3.09

Market cap

$164.68M

P/E (trailing)

—

P/E (forward)

-2.15

EPS (trailing)

$-1.86

Dividend yield

—

Beta

0.32

Avg. volume

460.6K

Forecasts

5 analyst ratings

Acumen Pharmaceuticals Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• ABOS

  Acumen Pharmaceuticals Inc. Common Stock

  $2.92

  ▼ 3.63%
  Market cap $164.68MP/E —
  $1.21$3.6
• LENZ

  LENZ Therapeutics Inc. Common Stock

  $5.12

  ▲ 6.34%
  Market cap $163.67MP/E —
  $4.54$50.4
• MOLN

  Molecular Partners AG American Depositary Shares

  $4.5

  ▼ 3.27%
  Market cap $163.47MP/E —
  $2.66$3.96
• CRBU

  Caribou Biosciences Inc. Common Stock

  $1.62

  ▼ 2.41%
  Market cap $162.66MP/E —
  $1.38$3.54
• HUMA

  Humacyte Inc. Common Stock

  $0.6538

  ▼ 5.66%
  Market cap $157.54MP/E —
  $0.5261$2.55
• TNYA

  Tenaya Therapeutics Inc. Common Stock

  $0.691

  ▼ 0.58%
  Market cap $157.50MP/E —
  $0.532$2.35
• ARMP

  Armata Pharmaceuticals Inc. Common Stock

  $5.24

  ▼ 3.50%
  Market cap $172.54MP/E —
  $2.4$16.34

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Acumen Pharmaceuticals, Inc. (ABOS) Q2 2026 Earnings Call Transcript
  SeekingAlpha · 8/12/2026
• Acumen Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation
  SeekingAlpha · 8/12/2026

• Derrell Porter · June 17, 2026 · Option Exercise

  13.0K @ $1.07
• Derrell Porter · June 17, 2026 · Sale

  13.0K @ $2.33
• Derrell Porter · June 16, 2026 · Sale

  12.8K @ $2.33
• Derrell Porter · June 15, 2026 · Option Exercise

  6.5K @ $1.07
• Derrell Porter · June 15, 2026 · Sale

  6.5K @ $2.35
• Nathan B. Fountain · June 9, 2026 · Sale

  6.4K @ $2.23
• Nathan B. Fountain · June 3, 2026 · Grant

  53.3K
• Nathan B. Fountain · June 3, 2026 · Grant

  35.5K
• John A. Stalfort III · June 3, 2026 · Grant

  53.3K
• John A. Stalfort III · June 3, 2026 · Grant

  35.5K
• Derrell Porter · June 3, 2026 · Grant

  53.3K
• Derrell Porter · June 3, 2026 · Grant

  35.5K
• Jeffrey L. Ives · June 3, 2026 · Grant

  53.3K
• Jeffrey L. Ives · June 3, 2026 · Grant

  35.5K
• George Golumbeski · June 3, 2026 · Grant

  53.3K

Institutional Ownership

March 31, 2026

Total shares held

45.96M

Total value held

$106.28M

Institutional holders

82